Madrigal Pharmaceuticals, Inc. (FRA:YDO1)

Market Cap	8.47B +19.0%
Revenue (ttm)	816.27M +432.1%
Net Income	-245.53M
EPS	-10.94
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	17
Open	370.10
Previous Close	371.70
Day's Range	362.50 - 371.30
52-Week Range	229.50 - 523.20
Beta	n/a
RSI	33.47
Earnings Date	Feb 19, 2026

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

• Industry: Pharmaceutical Preparations
• CEO: William Sibold
• Employees: 528
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YDO1

Financial Performance

In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.

Financial numbers in USD